Business
Tempo Project Update
Tempo Project Update.
About this update from Physiomics Plc
[{"type":"text","content":"\n RNS Number : 8247U Physiomics PLC 20 May 2008 \n \n\nPhysiomics plc\nThe Magdalen Centre\nThe Oxford Science Park\nRobert Robinson Avenue\nOxford\nOX4 4GAUK\n\nTel 01865 784980\nFax 08701 671931\n20 May 2008\nPhysiomics plc ('Physiomics' or 'the Company')\nUpdate on EC funded TEMPO project - Achievement of Milestone\nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that, following a successful mid-term review held in Oxford in March 2008 and evaluation of the results by the European Commission, the 3 years research program 'TEMPO' that commenced in September 2006 can continue as specified the original grant proposal. This three year programme was established to explore the effect of circadian rhythms (the body's clock) on changes in cancer cell proliferation and the effectiveness of cancer drugs with the knowledge that would be derived used to optimise treatment regimen of individual cancer patients. Physiomics is using its cell simulation technologies to study the effect of cancer drugs on the cell cycle/circadian clock system behaviour, at the cellular level and at the tissue level (by creating a virtual tumour). Then, using software to simulate pharmacokinetics, the profile of concentrations of drug in blood over time after dosing, Physiomics will help establish optimised dosing regimens and delivery schedules.\nPhysiomics was to expected to receive approximately £169,000 (€252,650) of matched funding over the three year period and if successful would have access to 3 to 5 new therapeutic schedules, optimised to patient profiles for 2 main drug classes against cancer. This knowledge will be used to enhance the Company's own drug discovery programmes.\nFollowing the approval by the commission, €88,480 of the initial pre-financing has been irrevocably granted to the company as consideration of the first year expenses and a second tranche of pre-financing has been received by the company for a total value of €87,840.\nDr Christophe Chassagnole, COO of Physiomics, said:\n'We are pleased that Physiomics' Systems Biology technology...